MODERN POSSIBILITIES OF IRON DEFICIENCY ANEMIA TREATMENT IN ONE VISIT

Abstract

The iron deficiency anemia remains a current problem, despite new methods of treatment. According to the statistics, every fifth woman of reproductive age has manifestations of iron deficiency that worsens quality of her life. The modern way of life causes need for fast and effective treatment. We carried out the analysis of information on treatment of an iron deficiency anemia by oral (ferri sulfas, ferric (III) hydroxide polymaltosate ) and intravenous (ferric (III) hydroxide olygoisomaltosate, ferric (III) carboxymaltosate, ferric (III) sacharose complex) iron preparations and red blood cell transfusion. On the basis of studying of scientific articles, we established that ferric (III) hydroxide olygoisomaltosate has the most effect and fast effect for treatment of iron deficiency medium and heavy gravity.

Keywords

anemia / iron deficiency / treatment of iron deficiency / ferri sulfas / ferric (III) hydroxide polymaltosate / ferric (III) hydroxide olygoisomaltosate / ferric (III) carboxymaltosate / ferric (III) sacharose complex / red blood cell transfusion

References

[1] WHO. The global prevalence of anaemia in 2011. Geneva: World Health Organization; 2015

[2] Румянцев А.Г., Масчан А.А., Чернов В.М., Тарасова И.С. Федеральные клинические рекомендации по диагностике и лечению железодефицитной анемии. Общественная организация «Национальное общество детских гематологов, онкологов»; ФГБУ «ФНКЦ ДГОИ им. Дмитрия Рогачёва» Минздрава России. М.; 2015: 3-4.

[3] Регистр лекарственных средств России. 2019. https://www.pda.risnet.ru (доступно 12.07.19).

[4] Видаль. Справочник лекарственных средств. https://www.vidal.ru (доступно 10.07.19).

[5] Компендиум 2018 - лекарственные препараты. https://www.compendium.com.ua (доступно 12.07.19).

[6] Kalra P., Bhandari S. Efficacy and safety of iron isomaltoside (Monofer®) in the management of patients with iron deficiency anemia. Intern. J. Nephrol. Renovasc. Dis. 2016; 9: 51-64.

[7] Bhandari S., Kalra P.A., Kothari J. et al. A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysispatients. Nephrol. Dial. Transplant. 2015; 30: 1577-89.

[8] Hildebrandt P.R., Bruun N.E., Nielsen O.W. et al. Effects of administration of iron isomaltoside 1000 in patients with chronic heart failure. A pilot study. Transfus. Alternat. Transfus. Med. 2010; 11(4):131-7.

[9] Dahlerup J.F., Jacobsen B.A., van der Woude J. et al. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anemia without profound changes in phosphate or fibroblast growth factor 23. Scand. J. Gastroenterol. 2016; 51:1332-8.

[10] Johansson P.I., Rasmussen A.S., Thomsen L.L. Intravenous iron isomaltoside 1000 (Monofer®) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination there of: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial). Vox. Sang. 2015; 109: 257-66.

[11] Reinisch W., Staun M., Tandon R.K., et al. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1000 (Monofer)compared with oral iron for treatment of anаemia in IBD (PROCEED). Am. J. Gastroenterol. 2013; 108:1877-88.

[12] Reinisch W., Altorjay I., Zsigmond F., et al. A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease. Scand. J. Gastroenterol. 2015; 50: 1226-33.

[13] Holm C., Thomsen L.L., Norgaard A., Langhoff-Roos J. Intravenous iron isomaltoside 1000 (Monofer) adminisered by a high single dose infusion or standard medical care for the treatment of fatigue in women after postpartum haemorrhage: a randomized controlled trial. Int. J. Gynecol. Obstet. 2015;131(Suppl. 5): E118.

[14] Wikstrom B., Bhandari S., Barany P., et al. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease. J. Nephrol. 2011; 24: 589-96.

[15] Kalra P.A., Bhandari S., Saxena S., et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol. Dial. Transplant. 2016; 31: 646-55.

[16] Birgegard G., Henry D., Glaspy J., et al. A randomized, noninferiority trial of intravenous iron isomaltoside versus oral iron sulfate in patients with nonmyeloid malignancies and anemia receiving chemotherapy, the PROFOUND trial. Pharmacotherapy. 2016; 36: 402-14.

[17] Klein H.G., Spahn D.R., Carson J.L. Red blood cell transfusion in clinical practice. Lancet. 2007; 370(9585): 415-26.

[18] Hébert P.C., Wells G., Blajchman M.A., et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N. Engl. J. Med.1999; 340(6): 409-17. [published correction appears. N. Engl. J. Med. 1999; 340(13):1056].

[19] Holm C., Thomsen L.L., Langhoff-Roos J. Intravenous iron isomaltoside treatment of women suffering from severe fatigue after postpartum hemorrhage. J. Matern., Fetal, Neonat. Med. 2019; 32(19): 2797-804. doi:10.1080/14767058. 2018.1449205

[20] Derman R., Roman E., Modiano M.R., Achebe M.M., Thomsen L.L., Auerbach M. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. Am. J. Hematol. 2017; 92: 286-91. https: //doi.org /10.1002 / ajh. 24633.

[21] Ganzoni A.M. Intravenous iron-dextran: therapeutic and experimental possibilities. Schweiz. Med. Wochenschr. 1970;100: 301-3.

[22] Subramanian R., Khardori R. Severe hypophosphatemia: pathophysiologic implications, clinical presentations, and treatment. Medicine (Baltimore). 2000; 79: 1-8.

[23] Liu P.Y., Jeng C.Y. Severe hypophosphatemia in a patient with diabetic ketoacidosis and acute respiratory failure. J. Chin. Med. Assoc. 2004; 67: 355-9.

[24] O’Connor L.R., Wheeler W.S., Bethune J.E. Effect of hypophosphatemia on myocardial performance in man. N. Engl. J. Med. 1977; 297: 901-3.

[25] Ognibene A., Ciniglio R., Greifenstein A., Jarjoura D., Cugino A., Blend D., et al. Ventricular tachycardia in acute myocardial infarction: the role of hypophosphatemia. South Med. J. 1994; 87: 65-9.

[26] Wolf M., Koch T.A., Bregman D.B. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J. Bone Miner. Res. 2013; 28: 1793-803.

[27] Bergwitz C., Jüppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annul. Rev. Med. 2010; 61: 91-104.

[28] Wolf M., White K.E. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr. Opin. Nephrol. Hypertens. 2014; 23: 411-9.

[29] Ring J., Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet. 1977; 1: 466-9.

[30] Озолиня Л.А., Керчелаева С.Б., Раздобреев И.А. Современные методы эффективной коррекции железодефицитной анемии в послеродовом периоде. Медицинский совет. 2017; (13): 26-32

[31] Holm C., Thomsen L.L., Norgaard A., Langhoff-Roos J. Single-dose intravenous iron infusion versus red blood cell transfusion for the treatment of severe postpartum anaemia: a randomized controlled pilot study. Vox Sanguinis. 2017; 112: 122-31. https://DOI:10.1111/vox.12475

RIGHTS & PERMISSIONS

Eco-Vector